Calling all sports tech startups ready to scale. Photo via Getty Images

Familiar names within Houston innovation have teamed up to launch a program for sports tech startups ready to scale.

Pokatok Labs announced five companies that make up its inaugural cohort. Pokatok is founded by Lawson Gow, founder of The Cannon; Chris Buckner, founder of Mainline; and Alex Gras, former chief commercial officer of The Cannon. (Note: Lawson Gow is the son of David Gow, the CEO of InnovationMap's parent company, Gow Media.)

The new program is targeting growing seed and series A startups across the scope of sports technology — health tech, gaming, fan experience, and more. The nine-week program is free to its cohort member and will run twice a year. Participating companies receive access to a network of organizations, advisors, investors, and subject matter experts within sports tech.

“Houston has a huge potential to emerge as a global leader in sports innovation, and the launch of this program is an important step in that direction,” says Gow, who serves as Pokatok's CEO.

The program will be housed in The Cannon Sports in 53West, which opened last year. Kate Evinger, who previously oversaw gBETA Houston's early stage accelerator, will lead Pokatok Labs as director.

“Each of the five companies are true disruptors within the global sports community. It is a privilege and an honor to be working alongside them, and we look forward to the great things to come from each '' Evinger says.

The first cohort of startups includes:

  • Detroit, Michigan-based Miro AI builds cutting-edge computer vision that analyzes images and videos to unlock athlete data. The technology has analyzed over 50 million athletes.
  • Monarc, headquartered in Dallas, has created a robotic quarterback called the Seeker. Several universities — like West Virginia University, Louisiana State University, and Washington University — have already tapped into the technology, as well as NFL professionals, including George Kittle, James White and Adrian Amos.
  • RE Cooling Tech, based in Lafayette, Louisiana, has a technology that cools and increases the performance of athletes before, during, and after physical exertion. The technology was validated in a study with The Korey Stringer Institute at the University of Connecticut showing efficacy in cooling and increased athletic performance.
  • Founded at MIT, Perch uses computer vision and machine learning to seamlessly track exercise, provide real time feedback, facilitate new types of competitions, and store the data for later analysis and progress tracking. The company has sold to more than 10 NFL teams, supporting two national championship college football teams, as well as a growing number of professional sports teams, colleges, military, high schools, performance facilities, and even individual home gyms.
  • Pennsylvania-based Reflexion is a portable neuro training service that gives athletes an edge with interactive lightboard based drills. Reflexion has raised over $4 million in venture funding to date, is used by thousands of athletes in homes and training centers, and is trusted by the likes of Under Armour, the Canadian National Soccer Team, and the Denver Nuggets.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.